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Probiotics  
• Definition  
Living microorganisms when administered in adequate 
amounts confer health benefits on the host 
Dr. Minoni Shirota
First developed L. casei Sirota
as a commercial product in 1935 
Probiotics – Daily example 
Cheese 
1. Fermented Milk Products 
Lassi
Frozen yogurt Ice cream 
Smoothie Milk  
Valio Gefilus® 20 years of probiotic dairy products in Europe 
Probiotics – Daily example 
2. Food & Drinks  3. Pharmaceutical products 
Mint candies 
Cereal Infant formula 
Candy & granola bars 
Cookies 
Probiotics supplement  
In form of: 
Tablets, Capsules, Granules 
Single or Cocktail of species 
Encapsulation help protect probiotics from:
-Air & moisture (esp. anaerobic species) 
-Stomach acid   
Dosage: 
109 – 1010 bacteria / day / adult 
Probiotics have several mechanisms of 
action that may contribute to human health
How about interactions with food toxins????
Hepatocellular Carcinoma 
(HCC)
• Hepatocellular carcinoma
(HCC) ranks as the fifth
most common cancer in 
the world with an 
estimating 473,000 new 
cases annually, 
accounting for 5.4% of 
all human cancer cases. 
• Late presentation, 
typically males aged 66 
with chronic liver 
disease.
• Median survival of 6 
months from time of 
diagnosis.
• Surgery is the only 
potentially curable form 
of treatment. 
Risk factors for HCC
• Viral
*Chronic hepatitis B 
*Chronic hepatitis C
• Preexisting liver disease
* Cirrhosis
-Metabolic liver disease
-Alcohol abuse
*Adenoma
• Environmental
*Aflatoxin
*Contraceptives and androgens
The aflatoxins
• Turkey “X” Disease
–Fungal infection by 
Aspergillus flavus and 
Aspergillus parasiticus
–Primary contamination
• High energy content 
foods  e.g. grain, nut 
and soy products
–Secondary contamination
• Dairy products, meat 
& eggs
Commodities in which aflatoxins 
have been detected
Flour Cocoa
Corn meal Cheese
Peanut Sausage
Meat pies Bread
Milk Macaroni
Cottonseed Copra
Cassava Cooked meat
Brazil nuts Pistachio nuts
Oilseeds Rice
Pumpkin seeds Soy
TOXIC EFFECTS OF AFLATOXIN
• Human
– Aflatoxin B1 is highly mutagenic, probably 
through mechanisms of epoxidation resulting 
in covalent binding to DNA. 
– A specific mutation at the third base of 
codon 249 of the tumor-suppressor gene p53 
has been described in HCC tissue and 
significantly associated with exposure to 
aflatoxin B1.

Populations at risk of aflatoxin exposure
Williams et al, Am J Clin Nutr 80:1106-1122, 2004
Chronic hepatitis B together with exposure 
to  dietary aflatoxins increases the risk 
of liver cancer
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HBV
(HBsAg)
Aflatoxins
(urinary
biomarkers)
HBV and 
aflatoxins
Adapted from Qian et al, 1994
No risk 
factors
Available options for solving the 
problem
Once food is contaminated with toxins, there are only two options 
if the food is to be used:
– the toxin can be removed
– the toxin can be degraded into less toxic or non-toxic 
compounds
Control measures
•Physical control (e.g. UV radiation, electronic sorting)
- suitable for very limited products
•Chemical control (e.g. ammoniation)
- health effects are not fully studied
•Monitoring AF levels and rejection of produce
- extremely costly option
Aflatoxins in food
Duodenum
Ileum
Liver
Absorption (portal circulation)
Systemic 
circulation
Blood
O
OO OCH3
O O
AFB1
Strategies for intervention at 
individual level
Jejunum
Feces (unabsorbed)
UrineBreast milk
Colon
Metabolism
Toxic 
products
Non toxic
products
Small
Aflatoxin
Portal vein
Liver
Blocking/reducing absorption of AFB1 from 
the small intestine
Aflatoxin + blocker
intestine
Unabsorbed
aflatoxins
Systemic
circulation
Unabsorbed
aflatoxins
Requirements for dietary tools of blocking/ 
reducing aflatoxin absorption in humans
• Part of normal human diet
• Long history of safe use
• Able to bind a range of harmful compounds including 
aflatoxins
• Binding takes place immediately and is stable under 
GIT conditions
• No effect on absorption of micro and macro 
nutrients
• Inexpensive and practical for food enrichments
Lactic acid bacteria 
(LAB)
• LAB involved in the production of fermented foods
o one quarter of our diet
o characterised by safe history
o extended shelf life compared to raw materials
• LAB has some health effects
o growth inhibition of food spoiling bacteria
o production of antimicrobial compounds
o probiotic effects as live organisms in food
Kinetic studies on binding
and release of toxins 
(dose-response)
In vitro binding assays with AF
Mechanisms of binding 
(chemical and structural factors)
In vitro toxicity studies 
(to examine if the binding 
will detoxicate the AFs)
Selection of bacteria with GRAS status 
(available commercially or isolated from microflora of 
healthy humans)
Selection of bacteria with good binding properties
of AFs and ability to deactivate AFs  
In vivo binding 
of AF
Clinical trials in populations exposed to AFs
(body burden and biomarkers)
Ex vivo ligated loop in chicks Feeding studies 
in animals
Stability of complex,
effect on absorption and bioavailability
• Certain strains of 
lactobacilli are capable 
of binding up to 80% of 
AFB1 in vitro (El-Nezami 
et al, 1996, 1998a,b,c), 
Fusarium toxins (El-
Nezami et al, 2002a,b, 
2004), PhIP and Trp-P-1 
(Haskard et al, 2001)
Aflatoxin is bound by probiotic bacteria – in 
vitro evidence
60
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LGG
LC705
acido
gasseri
Shirota
PJS
E. coli
• AFB1 is predominantly 
bound to a carbohydrate 
moiety on the surface of 
the bacteria (Haskard et 
al, 2002)
• The complex formed 
between the bacteria and 
AFB1 is stable under 
different conditions 
(Haskard et al, 2002, Lee 
et al, 2003)
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Period of incubation
El-Nezami et al, Food Chem Toxicol 1998
Ex vivo study in chicks
      
 The concentration of AFB1 ± SD extracted from 
Group Duodenal tissueb  Soluble fractionc Insoluble fraction of 
El-Nezami et al. (2000) ): Journal of Food Protection. , JGratz S. et al. (2005): Journal of Food 
Protection. 
of luminal fluid luminal fluid 
 
 1min 60 min 1 min 60 min 1 min 60 min 
AFB1 only 0.27 ± 0.09 ND  1.04 ± 0.36  0.05±0.01 ND ND 
LBGG+AFB1 0.07 ± 0.05 ND  0.48 ± 0.15  ND 0.76±0.04 1.38±0.16 
LC705+AFB1 0.17 ± 0.11 ND  0.58 ± 0.10  0.08 ± 0.06 0.54±0.10 1.07±0.12 
PJS+AFB1 0.10 ± 0.05 ND  0.67 ± 0.13  0.13 ± 0.02 0.55±0.11 1.24±0.06 
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Transport of AFB1
Intestinal AFB1 transport and toxicity
Caco-2 cells
Semi-permeable filter
Bacteria
apical
basolateral
Gratz S., et al. (2007) Applied and Environmental Microbiology.
• Transport of AFB1 through monolayer was reduced by GG
• AFB1 induced TER (membrane integrity) reduction was 
attenuated 
• AFB1 induced DNA damage was attenuated 
3210-1-23days
AFB1
Feces
Urine
Feces
Urine
Feces
Urine
Feces
Urine
Feces
Urine
Feces
Urine
± GG± GG± GG± GG± GG± GG
In vivo protective effects of probiotics against 
AFB1 toxicity
Feces
Urine
Blood (ALT)
Body weight
AFB1 (1.5 mg/kg bw, single dose on day 0)
GG (5x1010CFU, daily for 6 days)
Body weightBody weight
Rat results
GG administration:
• Increased fecal AFB1 by 122% 
• Increased fecal AFM1 by 152% 
• Decreased plasma AFB1-albumin by 29% 
• Decreased change in liver function (ALT) by 54%
• Prevented body weight loss
Gratz S., et al. (2006): Applied and Environmental Microbiology.
WHY CHINA?
• Primary liver cancer (PLC) is one of the most common cancers in 
China.
• There more than 250,000 new cases diagnosed yearly with liver 
cancer in China.
• The mortality rates both in rural and urban areas are 25 and 21 
per 100 000, respectively, in the EU 3 per 100,000.
• The main 3 factors for the development of liver cancer are 
prevalent in China. Aflatoxins are consistent contaminants of the 
food supply in China, HBV and HCV are endemics in China. 
• 500,000,000 individual infected with HBV
(250,000,000 in China)
• 170,000,000 individuals infected with HCV
(10,000,000 in China)
• 1,000,000 individuals dies annually because of complication 
associated with HBV, similar figure also expected for HCV 
(250,000 in China)
Intervention and 
sampling
Follow-up and 
aflatoxin 
measurement
Recruitment
300 healthy Chinese men  
screened for urinary AFM1
142 subjects had 
detectable level of AFM1
in their urine
The subjects were rando-
mized in two groups re-
ceiving either 2 placebo 
or 2 probiotic capsules/d
for 5 weeks 
*Bioprofit® containing 1010
cfu/capsule
Follow-up sample at day
70 (5 weeks after dis-
continuation of the  
treatments)
Fecal and urinary 
aflatoxin M and Q
Probiotic intervention in China
90 recruited based on  
physician’s examination 
and blood chemistry
Fecal, urine and blood 
samples were collected at 
baseline (day 1), and during 
intervention (days 21 and 
35). Additional fecal 
samples were collected at 
days 2,3,5.
1 1 
concentrations were 
measured by HPLC. AFB-
N7-guanine was used as a 
validated biomarker for 
reduction in HCC.
2Study days
(Follow-up) 
35
(Baseline)
21531
(Probiotic/placebo)
70
Metabolic transformation of 
aflatoxin B1
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Probiotic 
Placebo 
Probiotic supplementation reduces the urinary 
excretion of AFB1–N
7-guanine, a biomarker of 
biologically effective dose of exposure to AFB1
Baseline W eek 3 W eek 5 Follow-up
U
r
i
n
a
r
y
 
A
F
B
1
-
N
7
-
g
u
a
n
i
n
e
 
(
n
g
/
m
l
)
0,1
0 ,2
0,3
0,4
El-Nezami et al, Am J Clin Nutr, 2006
What our findings mean?
Egner et al, Mutation Res 523-524:209-216, 2003
